InTray™ GC

ITEM:
11-080-002
Proprietary modified agar that is selective for gonococcal bacteria.

To view product variations and purchase, please login in below.

Specifications

Product Principle:

  • Combine collection, culture and transport into one IVD device.
  • Modified Thayer Martin medium, selective for GC  [2]
  • “Ready to Start” activatable 5% CO2 environment
  • Highly selective prepared media in a device designed for in-vitro culture and incubation

Simple Convenience:

  • No expensive CO2 incubator required
  • InTray is designed for specimen collection/ inoculation at point-of-care
  • Saves time, material cost and waste, reducing exposure to collected sample

Accurate Detection:

Test Strain Result
Neisseria gonorrhoeae Growth
Neisseria meningitidis Growth
Candida albicans Inhibited
Escherichia coli Inhibited
Proteus mirabilis Inhibited
Staphylococcus epidermidis Inhibited
Neisseria sicca Inhibited

Time Result:

  • Incubate InTray GC flat to avoid moisture leaking into the CO2 pill chamber. Incubate the tray right side up for 24–72 hours at 35°C (95°F) under ambient atmosphere.
  • If InTray GC is being used for transport, to any laboratory located outside of the facility where collection was performed, then pre-incubation at 35°C for 24 hours is required.
  • After the pre-incubation step, InTray GC can be transported up to 72 hours at ambient temperature (18-25°C) to the testing laboratory for analysis.

Storage:

  • Extended 12 month shelf life from the date of manufacture
  • InTrayGC is compatible with storage at room temperature. However, for optimal performance store at 2-8˚C
  • Do not freeze.
  • InTray GC can be transported up to 72 hours at ambient temperature (18-25°C) to the testing laboratory for analysis.

Specimen:

  • Oral swab
  • Rectal swab
  • Genitourethral swabs
  • Pharyngeal Swab

CPT Codes:

  • 87081  |  87088  |  87070

Detects

Neisseria gonorrhoeae

Features

01.    SHELF-LIFE AND DURABILITY

  • Extended 12-month shelf life from date of manufacture
  • Designed for specimen collection/inoculation at point-of-care — a fully enclosed IVD for incubation, culture and observation.
  • The sealed prepared media device selectively cultures fastidious N. gonorrhoeae species

02.    KEY FEATURES

  • Fully enclosed IVD with integrated, activatable 5% CO2 system
  • Nutritive growth media for selectivity and specificity

03.    EXPERIENCE A REDUCTION IN:

  • Time-to-result
  • Materials waste
  • Risk of exposure and contamination

04.    InTray GC’s dynamic built-in components and features are designed for user compatibility and ease of detection. The following are key highlights that come with this product:

  • Single exposure system
  • A “ready to start” 5% CO2 environment
  • Modified Thayer Martin medium, selective for N. gonorrhoeae
  • Direct observation of the culture with anti-fog viewing
  • Incubatory and transport capabilities
  • Extended 12-month shelf-life

Product Details

Whitepapers and Articles

Global Healthcare Detection and Response

Centers for Disease Control and Prevention and National Center for Emerging and Zoonotic Infectious Diseases.

Read ►

 

CDC Doubles Dose of Ceftriaxone for Gonorrhea

Neisseria gonorrhoeae infections have increased by 63 percent, with growing incidence of antibiotic resistance. Antimicrobial stewardship is the driver of CDC recommendations, highlighting the importance of definitive therapy at the first contact with the patient.

Read ►

 

Down to one Effective Treatment

CDC

Read ►

 

The CDC has declared Neisseria Gonorrhoeae infections to be one of the most important threats of antibiotic resistance in the United States and the world.

Read Paper ►

 

Two-Thirds of cases are Missed!

The Lancet

Read Article ►

 

Recovery of Neisseria gonorrhoeae from 4 commercially available transport systems

John R. Papp

Diagnostic Microbiology and Infectious Disease Volume 86, Issue 2, October 2016, Pages 144-147

Read Paper ►

 

Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present

M Bodie

Can Commun Dis Rep. 2019 Feb 7; 45(2-3): 54–62

Read Paper ►

 

Gonococcal antimicrobial susceptibility surveillance in Europe

Results summary 2017

Diagnostic Microbiology and Infectious Disease Volume 86, Issue 2, October 2016, Pages 144-147

Read Report ►

 

Related Products

Your cart is currently empty.

Return to shop